文献速递治疗药物监测与药物基因组学肝肾功能剂量调整特殊人群用药

儿童替考拉宁药代动力学系统综述

Pharmacokinetics of teicoplanin in paediatric patients-A systematic review of current literature.
PubMed 文献 · Br J Clin Pharmacol · 2025-10-27

结果显示儿童替考拉宁药代动力学变异大,肾功能、疾病和年龄可部分解释变异,危重和肿瘤患儿清除率更高,目标谷浓度常未达到,治疗药物监测可能改善疗效。

要点

  • 儿童替考拉宁药代动力学变异大,目标谷浓度常难达到。
  • 肾功能、疾病状态和年龄可部分解释药代动力学变异。
  • 危重和肿瘤患儿清除率更高,危重患儿表观分布容积略高。

核心结论

  • 儿童替考拉宁药代动力学高度变异,目标谷浓度常未达到,难以给出通用剂量推荐。
  • 未来研究应定义适应症依赖的目标值,治疗药物监测可能改善临床疗效。
  • 明确游离药物暴露及其临床相关性应作为未来研究优先事项。

研究设计与样本

  • 纳入随机对照试验、非随机对照试验或前瞻性/回顾性队列研究,评估儿童替考拉宁药代动力学或暴露。

主要发现

  • 新生儿、婴儿、≥1岁儿童、肾功能损害儿童、危重儿童和儿童肿瘤患者等亚组间药代动力学存在显著变异。
  • 肾功能、疾病和年龄等协变量可部分解释药代动力学变异。
  • 危重和儿童肿瘤患者中清除率更高。
  • 与其他人群相比,危重儿童的表观分布容积似乎略高。
  • 清除率与肾功能呈正相关。

关键数值与推荐

  • 目标谷浓度常未达到。

临床怎么用

  • 治疗药物监测可能有助于改善儿童替考拉宁的临床疗效。
  • 由于药代动力学变异大且目标谷浓度常未达到,通用剂量推荐具有挑战性。

局限性

  • 未来研究需定义适应症依赖的目标值。
  • 游离药物暴露及其临床相关性尚需明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Teicoplanin is commonly used in children to treat gram-positive infections and is sometimes used off-label prophylactically in surgical or paediatric oncology settings. The pharmacokinetics (PK) of teicoplanin in children exhibit considerable variability, such as in critically ill children or those with renal impairment. This systematic review aims to summarize and evaluate reported PK data and target attainment, identify PK variations and provide dosing recommendations when available. METHODS: A systematic literature search was performed in PubMed and Embase, following PRISMA 2020 guidelines. Included studies were randomized controlled trials, nonrandomized controlled trials or prospective/retrospective cohort studies, published up to December 2024, that assessed PK or teicoplanin exposure in children. Data on PK, target attainment, efficacy, and toxicity were extracted. RESULTS: Twenty-six articles were included in the final analysis, revealing significant PK variability among subgroups (neonates, infants, children aged ≥1 year, children with renal impairment, critically ill children and paediatric oncology patients). This variability is partially explained by covariates such as kidney function, illness and age. In critically ill and paediatric oncology patients, clearance (CL) was higher. Compared with other populations, the volume of distribution (Vd) in critically ill children appeared somewhat higher. A positive correlation between CL and kidney function was identified. CONCLUSION: Teicoplanin PK in children is highly variable, with target trough levels often not achieved, making universal dosing recommendations challenging. Future studies should define indication-dependent targets. Therapeutic drug monitoring could improve clinical efficacy. Defining unbound exposure and its clinical correlates should be a priority for future research.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Wijnen NE, Touw DJ, Klein K, et al. Pharmacokinetics of teicoplanin in paediatric patients-A systematic review of current literature. Br J Clin Pharmacol. 2025. PMID: 41145240. doi:10.1002/bcp.70309

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。